Colorectal cancer with microsatellite instability and immunotherapies
Colorectal cancer with microsatellite instability and immunotherapies
Sebastian Stintzing (M.D.), Professor of Medicine, is Head of the Division of Oncology and Haematology, Department of Medicine (CCM), Charité Universitaetsmedizin Berlin. His research focuses on predictive and prognostic biomarkers in the treatment of GI cancer with a special focus on colorectal cancer. From 2012 to 2014, he was a research fellow at the Sharon Carpenter Laboratory at the University of Southern California Norris Comprehensive Cancer Center, Los Angeles, U.S.A. He coordinated the translational part and assisted the clinical study conduct of several studies and earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer. In 2012, he received the prestigious Research Fellowship Award from the German Cancer Aid in Germany and started work at the University of Southern California. Dr Stintzing is member of national and international cancer associations and speaker of the steering committee of the working group Colorectal Carcinoma of the German AIO.
AMGEN, Bayer, BMS, Isofol, Lilly, Merck KGaA, MSD, Pierre Fabre, Roche, Sanofi, Taiho, Takeda
Looking beyond the obvious mutations in non-small-cell lung cancer
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Make decisions for your patient at two key stages in their journey
Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED
Share the survey with patients with lung cancer and their caregivers
Explore pre-analytical phase challenges and biomarker testing in lung cancer. Moderated by the Oncology Brothers.